>>Dr. Paul Laikind, president and chief executive officer. "With respect to our metabolic disease product candidates, the clinical evaluation of CS-917, our novel product candidate for the treatment of type 2 diabetes, continues in the important Phase 2b clinical trial being conducted by our partner Daiichi Sankyo. They appear to be on target to have initial results of the trial in the first half of 2007. Our second Phase 1 clinical trial for our second generation product candidate for treating type 2 diabetes, MB07803, is on track to be completed around the end of the year, with a Phase 2 trial expected to start early in 2007. And last month, we initiated the first Phase 1 trial for MB07811, a novel product candidate for the treatment of elevated cholesterol and our fifth internally discovered product candidate to enter the clinic."<<
From the 3rd Q PR. I guess I need to see what the latest in timelines is, check out the latest presentation. They're running a little behind with MB07803. MBRX is at a reasonable support level now, and I am comtemplating starting a position. Probably a half position, as I think the the 2b results for CS-917 are going to be a bit binary. Anybody got a feel for outcome?
I'll listen to the most recent webcast I can find and try to get my own feel, but second opinions are always welcome.
Cheers, Tuck |
